Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

Open access
Paiva, Bruno, Martinez-Lopez, Joaquin, Vidriales, Maria-Belen, Mateos, Maria-Victoria, Montalban, Maria-Angeles, Fernandez-Redondo, Elena, Alonso, Lourdes, Oriol, Albert, Teruel, Ana-Isabel, de Paz, Raquel, Laraña, José-Garcia, Bengoechea, Enrique, Martin, Alejandro, Mediavilla, Joaquin Diaz, Palomera, Luis, de Arriba, Felipe, Bladé, Joan, Orfao, Alberto, Lahuerta, Juan-Jose, San Miguel, Jesus F.·2011·Journal of Clinical Oncology

Abstract

To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated with novel agents.Patients and Methods: From a total of 260 elderly patients newly diagnosed with MM included in the GEM05>65y trial, 102 patients achieving at least a partial response with ≥ 70% reduction in M-component after the six planned induction cycles were simultaneously analyzed by immunofixation, sFLC, and multiparameter flow cytometry (MFC) immunophenotyping; this population is the focus of this study. Results: Forty-three percent of patients achieved CR, 30% achieved stringent CR, and 30% achieved IR. Patients in stringent CR showed no significant survival advantage compared with those in CR, whereas patients in IR showed significantly increased progression-free survival (PFS) and time to progression (TTP) compared with those in stringent CR or CR; this was confirmed by multivariate analysis (hazard ratio, 4.1; P = .01 for PFS). Discrepancies between the three techniques were relatively common. Notably, in all seven patients achieving IR but remaining immunofixation positive, the M-component disappeared in follow-up analysis. In contrast, MFC-positive patients who were immunofixation negative (n = 20) showed a tendency toward early reappearance of the M-component (median, 3 months). Similarly, in five of 11 stringent CR but MFC-positive patients, symptomatic disease progression was recorded at a median of 13 months after induction. Conclusion: Achieving an IR translates into superior PFS and TTP compared with conventional CR or stringent CR. These techniques provide complementary information and thus, an effort should be made to refine response criteria in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2010.33.1967

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 233

Metadata

Authors
Paiva, B., Martinez-Lopez, J., Vidriales, M.-B., Mateos, M.-V., Montalban, M.-A., Fernandez-Redondo, E., Alonso, L., Oriol, A., Teruel, A.-I., de Paz, R., Laraña, J.-G., Bengoechea, E., Martin, A., Mediavilla, J. D., Palomera, L., de Arriba, F., Bladé, J., Orfao, A., Lahuerta, J.-J., & San Miguel, J. F.
Venue
Journal of Clinical Oncology
Published
2011-04-20
Volume
29
Issue
12
Pages
1627-1633
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2108485762
Cited by
233
References
4
FWCI
13.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. https://app.cochat.ai/papers/10.1200/jco.2010.33.1967
The paper
Paiva, B., Martinez-Lopez, J., Vidriales, M.-B., Mateos, M.-V., Montalban, M.-A., Fernandez-Redondo, E., Alonso, L., Oriol, A., Teruel, A.-I., de Paz, R., Laraña, J.-G., Bengoechea, E., Martin, A., Mediavilla, J. D., Palomera, L., de Arriba, F., Bladé, J., Orfao, A., Lahuerta, J.-J., & San Miguel, J. F. (2011). Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.1967

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.